Jim Cramer recommended buying Johnson & Johnson (JNJ) shares during a recent dip, citing upcoming data from the Psych Congress conference and strong sales growth. Despite a 2.33% drop in the session, JNJ has outperformed the market with a 53.76% gain over the past year and raised its 2026 sales outlook. Key products like Caplyta and Spravato, along with oncology drugs, are driving growth. Investors should watch for upcoming data readouts and the planned Orthopaedics business separation later this year.
Johnson & Johnson announced new pivotal Phase 3 clinical data for CAPLYTA (lumateperone) in treating bipolar mania, alongside additional findings in bipolar depression and major depressive disorder. The data, presented at the 2026 Psych Congress, hig...
The JPMorgan Equity Premium Income ETF (JEPI) delivers attractive monthly income by selling call options, which caps its upside potential. In contrast, three Dividend Kings—Coca-Cola, Johnson & Johnson, and Procter & Gamble—offer lower initial yields...
In 2026, among defensive stocks, Johnson & Johnson outperformed with a 35% gain driven by strong oncology and immunology sales and a robust pipeline. Coca-Cola followed with a 28% rise, benefiting from steady global volume and pricing power, while Pr...
Johnson & Johnson has increased its dividend for the 64th consecutive year, paying $1.34 per share quarterly, reflecting a 3.1% raise. The company maintains a strong financial position with a payout ratio near 48%, supported by robust operating cash ...
